PhaseBio Pharmaceuticals - PHAS Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PhaseBio Pharmaceuticals in the last twelve months. There are currently 5 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PHAS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PHAS, but not buy additional shares or sell existing shares.
View PHAS analyst ratings or view top-rated stocks.

5 Wall Street analysts have issued twelve-month price targets for PhaseBio Pharmaceuticals' shares. Their PHAS share price forecasts range from $1.00 to $8.00. On average, they expect the company's stock price to reach $4.50 in the next twelve months. This suggests a possible upside of 8,990.9% from the stock's current price.
View analysts price targets for PHAS or view top-rated stocks among Wall Street analysts.

PhaseBio Pharmaceuticals' stock was trading at $2.61 at the start of the year. Since then, PHAS stock has decreased by 98.1% and is now trading at $0.0495.
View the best growth stocks for 2022 here.

PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) announced its earnings results on Wednesday, November, 10th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.59) by $0.07. The firm earned $0.34 million during the quarter, compared to analysts' expectations of $2.67 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other PhaseBio Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), Selecta Biosciences (SELB), Sorrento Therapeutics (SRNE), Amarin (AMRN), Vaxart (VXRT) and Agile Therapeutics (AGRX).

(PHAS) raised $66 million in an initial public offering (IPO) on Thursday, October 18th 2018. The company issued 5,000,000 shares at a price of $12.50-$14.00 per share. Citigroup, Cowen and Stifel acted as the underwriters for the IPO and Needham was co-manager.

PhaseBio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHAS."

PhaseBio Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Resources Investment Advisors LLC. (0.34%). Insiders that own company stock include Clay Thorp, Edmund Harrigan, Enterprise Associates 13 L New and Glen Burkhardt.
View institutional ownership trends.

Shares of PHAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PHAS stock can currently be purchased for approximately $0.05.

PhaseBio Pharmaceuticals (NASDAQ:PHAS) has a market capitalization of $2.47 million and generates $10.83 million in revenue each year. The company earns $-131,070,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis.

PhaseBio Pharmaceuticals' mailing address is 1 Great Valley Parkway Suite 30, Malvern PA, 19355. The official website for the company is www.phasebio.com. The company can be reached via phone at (610) 981-6500 or via email at pmobley@nobleromans.com.